Real-World Evidence (RWE) as a Marketing Asset
In 2026, "Evidence-Based Marketing" has replaced traditional creative-led advertising in Germany.
Pharmaceutical companies are using Big Data to generate Real-World Evidence (RWE) that demonstrates a drug’s effectiveness in the diverse German patient population (e.g., elderly patients with multiple comorbidities). This data is used as the core of advertising collateral for the G-BA (Federal Joint Committee) and hospital procurement boards. Instead of generic efficacy claims, 2026 advertisements now lead with "Real-World Impact" metrics, using data visualizations that show how the therapy reduces hospital stays or improves quality of life within the German statutory health insurance system.
3 Views